No Data
No Data
Nanjing Vazyme Biotech's Unit Gets Approval to Sell Two Medical Devices in Europe
Novogene (688105.SH): Subsidiary's product obtains EU CE IVDR certification.
On July 16, Gelonhui reported that Nouveau Life Sciences (688105.SH) announced that some products of its wholly-owned subsidiary, Nanjing Nouveau Life Sciences Medical Technology Co., Ltd., have recently obtained EU CE IVDR certification and can be sold in EU countries and countries that recognize EU CE certification. The fully automatic medical PCR analysis system and matching sample preservation solution obtained by the company this time can be used with microfluidic chips (test kits) to control fluids through digital microfluidic chip technology, and complete nucleic acid extraction, amplification, and detection of the test sample in the microfluidic chip.
Private Companies Invested in Nanjing Vazyme Biotech Co.,Ltd (SHSE:688105) up 5.3% Last Week, Insiders Too Were Rewarded
Voluntary disclosure announcement of Noritz's 2024 interim performance forecast.
Nuoweizan (688105. SH) has spent 100 million yuan to repurchase 1.02% of its shares.
Zhicheng Finance and Economics APP learned that NOWIYIZAN (688105.SH) announced that as of June 28, 2024, the company had repurchased a total of 4.0866 million shares of the company through the Shanghai Stock Exchange system by centralized bidding trading method, accounting for 1.02% of the total share capital of the company. The minimum price of repurchase transaction was 22.63 yuan/share and the maximum price was 28.65 yuan/share. The accumulative payment was 100 million RMB (excluding transaction fees).
Annual equity distribution of Nuoweizan (688105.SH) in 2023: 1 yuan per 10 shares. Registration for stock rights on July 5th.
Nuoweizan (688105.SH) released the Annual Equity Dividend Implementation Announcement for 2023, implementing equity dividend rights...
No Data